| |
|
|
Daewoong Pharmaceutical (069620) |
|
|
STOCK |
|
|
| Address |
223-23, SANGDAEWON 1-DONG, GYEONGGI |
| Home Page |
www.daewoong.co.kr
|
| Established |
2002.10. 2 |
Tel |
031-741-7700 |
| Listed |
2002.11. 1 |
IR |
02-550-8138 |
| Common shares O/S |
10,427,047 |
President |
Lee,Jong Uk/Yun,Jae Hun |
| Preferred shares O/S |
|
No.of Employees |
1,260(2009. 9) |
| Sales of its key products such as Urso increased. Profitability declined as a weaker currency boosted import prices of raw materials. Financial status remained stable on the back of ample liquidity and low debt. |
| Sales of new products such as Zanubia are expected to increase, while demand for existing products is expected to wane down the road. Profitability improved as a stronger currency helps reduce costs of raw materials. Financial status is expected to remain stable on its good cash flows, although it plans facility investment. |
|
  |
(date: 2009.06, unit : %) |
| Name |
Daewoong |
Dae Woong Foundation |
Yoon Yeonghwan |
| Portion |
40.2 |
5.0 |
3.4 |
|
 |
(unit : %) |
| Sales |
Olmesartan medoxomil |
14.7 |
Cost |
Raw Materials |
|
| Ursa |
8.9 |
Labors |
|
| Others |
56.4 |
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
02.11 |
08. 4 |
09. 4 |
- |
- |
| Type |
LI |
BI |
BI |
- |
- |
| Amount |
246.96 |
6.84 |
6.87 |
- |
- |
|
|
|
|
